πŸ“–
CD20 antibody-based combination therapy may reduces the adverse prognostic impact of M-protein positivity in marginal zone lymphoma.
Zhang Y, Hu W, Fang Y, Zheng B, Zhang Y, Chen W, Li R

CD20 antibody-based combination therapy may reduces the adverse prognostic impact of M-protein positivity in marginal zone lymphoma.

Medicine & Health Published 2026 Verification Pending

Overview & Synopsis

Open access biomedical research article published in Leuk Res Rep.

Advertisement
SPONSOR CONTENT
Indexed from repository: PubMed Central (pmc.ncbi.nlm.nih.gov)
Loading document from verified source...
Keyboard Shortcuts: ← / → for pages • + / - for zoom • 0 to fit width Powered by Mozilla PDF.js v3.11

Document Information

Document Title CD20 antibody-based combination therapy may reduces the adverse prognostic impact of M-protein positivity in marginal zone lymphoma.
Author / Organization Zhang Y, Hu W, Fang Y, Zheng B, Zhang Y, Chen W, Li R
Subject & Discipline Leuk Res Rep
Categories Medicine & Health
Publication Year 2026
License / Rights Open Access / Creative Commons
Resource Verification Listed PDF (Verification Pending)
Original Host Website PubMed Central (pmc.ncbi.nlm.nih.gov)
File Format application/pdf (Portable Document Format)
Language EN
Catalog ID DOC-26558
Original Source Link Visit Source Page on pmc.ncbi.nlm.nih.gov »